ASCENDE-RT∗, a randomized trial of brachytherapy: First report of the pilot with a median 52m followup: Cancer outcomes, treatment-related toxicity and patient-reported QOL
William Morris(Vanderbilt University), Ingrid Spadinger, Mitchell C. Liu(BC Cancer Agency), Michael McKenzie(Provincial Health Services Authority), Graeme Duncan(BC Cancer Agency), Eric Berthelet(University of British Columbia), Jonn Wu, William Kwa
Cited by 1
Related Papers
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial
|The Lancet Oncology|2019|459
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319